Literature DB >> 11834647

Effects of acetazolamide and furosemide on ventilation and cerebral blood volume in normocapnic and hypercapnic patients with COPD.

Marjo J T van de Ven1, Willy N J M Colier, Marco C van der Sluijs, Berend Oeseburg, Piet Vis, Hans Folgering.   

Abstract

STUDY
OBJECTIVES: Effects of chronic metabolic alkalosis and acidosis and their relation to central chemoregulation may differ between normocapnic and chronic hypercapnic patients with COPD. The relationship between responses of inspired ventilation (VI), mouth occlusion pressure (P(0.1)), and cerebral blood volume (CBV), to short-term changes in arterial PCO(2) was measured. PATIENTS AND METHODS: Seventeen patients with chronic hypercapnia and COPD (PaCO(2) > 6.0 kPa) and 16 normocapnic patients with COPD (PaCO(2) < or = 6.0 kPa) [FEV(1) 27% predicted] were studied under baseline metabolic conditions and after 1 week of treatment with oral furosemide, 40 mg/d, or acetazolamide, 500 mg/d. Hypercapnia (change in end-tidal carbon dioxide > 1 kPa) was induced by administering adequate amounts of carbon dioxide in the inspired air. CBV was measured using near-infrared spectroscopy.
RESULTS: Compared with baseline metabolic condition, chronic metabolic acidosis and alkalosis did not change ventilatory (Delta VI/Delta PaCO(2)) and cerebrovascular (Delta CBV/Delta PaCO(2)) reactivity. Base excess (BE) decreased by 6.8 +/- 1.1 mEq/L and 6.9 +/- 1.6 mEq/L, respectively, in the normocapnic and chronic hypercapnic COPD groups during metabolic acidosis, resulting in a not-quite-significant leftward shift of both the ventilatory and cerebrovascular carbon dioxide response curve. BE increased by 2.3 +/- 1.2 mEq/L and 1.2 +/- 1.3 mEq/L, respectively, during chronic metabolic alkalosis in both COPD groups, without concomitant shift. Poor correlations between ventilatory and cerebrovascular carbon dioxide responsiveness (Delta CBV/Delta PaCO(2) and Delta VI/Delta PaCO(2), Delta CBV/Delta PaCO(2) and Delta P(0.1)/Delta PaCO(2), respectively) were found irrespective of baseline, respiratory condition, and induced metabolic state.
CONCLUSIONS: Normocapnic and chronic hypercapnic COPD patients have the same ventilatory and cerebrovascular carbon dioxide responsiveness irrespective of induced metabolic state.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11834647     DOI: 10.1378/chest.121.2.383

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  Effectiveness of acetazolamide for reversal of metabolic alkalosis in weaning COPD patients from mechanical ventilation.

Authors:  Christophe Faisy; Amel Mokline; Olivier Sanchez; Jean-Marc Tadié; Jean-Yves Fagon
Journal:  Intensive Care Med       Date:  2010-03-09       Impact factor: 17.440

2.  Obesity Hypoventilation Syndrome.

Authors:  Safal Shetty; Sairam Parthasarathy
Journal:  Curr Pulmonol Rep       Date:  2015-03-01

3.  Blunted ventilatory response to hypoxia/hypercapnia in mice with cigarette smoke-induced emphysema.

Authors:  F Xu; J Zhuang; R Wang; J C Seagrave; T H March
Journal:  Respir Physiol Neurobiol       Date:  2007-04-08       Impact factor: 1.931

4.  Mixed acid-base disorders, hydroelectrolyte imbalance and lactate production in hypercapnic respiratory failure: the role of noninvasive ventilation.

Authors:  Claudio Terzano; Fabio Di Stefano; Vittoria Conti; Marta Di Nicola; Gregorino Paone; Angelo Petroianni; Alberto Ricci
Journal:  PLoS One       Date:  2012-04-23       Impact factor: 3.240

5.  Efficiency of Nebulizing Furosemide in the Treatment of Chronic Pulmonary Obstructive Disease: A Systematic Review and Meta-Analysis of Clinical Trials.

Authors:  Abas Ghaysouri; Gholam Basati; Morteza Shams; Hamed Tavan
Journal:  Tanaffos       Date:  2020-12

Review 6.  COPD and stroke: are systemic inflammation and oxidative stress the missing links?

Authors:  Victoria Austin; Peter J Crack; Steven Bozinovski; Alyson A Miller; Ross Vlahos
Journal:  Clin Sci (Lond)       Date:  2016-07-01       Impact factor: 6.124

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.